Larimar Therapeutics president and CEO Carole Ben-Maimon acquires $49,953 in stock
IN
Investing.comBy Investing.com
EXECUTIVE SUMMARY
Larimar Therapeutics president and CEO Carole Ben-Maimon acquires $49,953 in stock....
Key Takeaways
- Larimar Therapeutics president and CEO Carole Ben-Maimon acquires $49,953 in stock.
Read Complete Original Article
Published originally on Investing.com



